Azarkeivan Azita, Nasiritoosi Mohsen, Kafiabad Sedigheh Amini, Maghsudlu Mahtab, Hajibeigi Bashir, Hadizadeh Mohammad
Department of Thalassemia Clinic, Blood Transfusion Research center, High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic, Tehran, Iran.
Asian J Transfus Sci. 2011 Jul;5(2):132-5. doi: 10.4103/0973-6247.83237.
Screening tests on blood bags is important step for blood safety. In Iran, screening for HCV started from 1996. We decided to determine the new cases of hepatitis C in our thalassemic patients, after screening of blood bags was initiated and trace backing from recipients to find their donors.
The study was done on patients with complete files for HCVAb test results. Only cases that had a positive HCVAb result following a negative result were considered as new cases. For trace backing, we recorded the blood transfusions' date and the blood bags' number from last negative test results (HCVAb) to the first positive test result. These data were sent to the transfusion center. The suspected donors were contacted and asked to be tested again in the transfusion center.
A total of 395 patients were studied; 229 (58%) males and 166 (42%) females. Mean age was 27.5 years. We had 109 HCV (27.5%) positive cases of whom 21 were infected after 1996. We traced the last five cases contaminated during 2003 and 2004. These five patients had 13, 10, 13, 12, and 6 donors, respectively (totally 54 donors were found). We proved the healthy state in 68.5% (37 of 54) of our donors population. Of them, 81% were repeated donors and 17 of 54 donors (31.5%) could not be traced (because of change in addresses). We did not have any HCV new cases after 2004.
We could not prove HCV transmission from donors as the source of infection. Although parenteral transmission is always on top of the list in HCV infection, the possibility of hospital and/or nursing personnel transmission and/or patient-to-patient transmission such as use of common instruments like subcutaneous Desferal(®) infusion pumps; which the patients used for iron chelation therapy, should also be kept in mind.
对血袋进行筛查是保障血液安全的重要步骤。在伊朗,丙型肝炎病毒(HCV)筛查始于1996年。在开始对血袋进行筛查并从受血者追溯至供血者后,我们决定确定地中海贫血患者中的丙型肝炎新病例。
本研究针对有完整HCV抗体检测结果档案的患者进行。只有HCV抗体检测结果从阴性转为阳性的病例才被视为新病例。为了追溯,我们记录了从上次阴性检测结果(HCV抗体)到首次阳性检测结果期间的输血日期和血袋编号。这些数据被发送至输血中心。联系疑似供血者并要求他们在输血中心再次接受检测。
共研究了395例患者;其中男性229例(58%),女性166例(42%)。平均年龄为27.5岁。我们有109例HCV阳性病例(27.5%),其中21例是在1996年后感染的。我们追溯了2003年和2004年期间受污染的最后5例病例。这5例患者分别有13名、10名、13名、12名和6名供血者(共找到54名供血者)。我们证实了68.5%(54名中的37名)供血者群体的健康状况。其中,81%是重复供血者,54名供血者中有17名(31.5%)无法追溯(因地址变更)。2004年后我们没有发现任何HCV新病例。
我们无法证明供血者是感染源导致HCV传播。虽然在HCV感染中,经肠道外传播始终是首要传播途径,但医院和/或医护人员传播以及/或患者之间传播的可能性,如使用皮下去铁胺(Desferal®)输液泵等患者用于铁螯合治疗的共用器械,也应予以考虑。